Immix Biopharma, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company with common stock registered under ticker IMMX and a development program centered on NXC-201 for relapsed/refractory AL Amyloidosis. Current reports include Regulation FD and other-event disclosures for NEXICART-2 clinical updates and regulatory-development matters.
The company’s SEC record also covers capital-structure activity, including at-the-market sales agreements, shelf registration statements, registered offerings, private placements, warrants and resale registration rights. Proxy materials disclose director elections, auditor ratification, annual-meeting voting results and other governance matters.
Helen C. Adams, Director of Immix Biopharma (IMMX), reported the following insider trading activity on June 28, 2025:
- Received a stock option grant to purchase 33,000 shares of common stock at an exercise price of $2.24 per share
- The options were granted on June 20, 2025, with an expiration date of June 20, 2035
- Vesting schedule: Equal monthly installments over 12 months, contingent on continued board service
- Currently holds 174,754 shares of common stock directly
This Form 4 filing reflects standard board compensation practices through equity grants. The transaction was executed pursuant to the company's director compensation program, with the options granted at fair market value.
Immix Biopharma, Inc. (IMMX) – Form 4 insider filing dated 06/23/2025
Director Jane Buchan reported one equity award and updated share ownership as of 06/20/2025:
- New derivative grant: 33,000 non-qualified stock options with an exercise price of $2.24 per share, expiring 06/20/2035. The options vest in 12 equal monthly installments beginning on the grant date, contingent on continued service (Note 1).
- Post-transaction ownership: 22,455 shares of common stock held directly. No common shares were bought or sold in the reported period; the table only updates the total beneficial ownership.
No cash consideration was paid for the option grant (price listed as $0.00), indicating a routine director compensation award. The filing does not disclose any simultaneous open-market transactions, earnings data, or major corporate events.
Investors should note that while option grants can create future dilution if exercised, the 33,000-share award is relatively small and vests over one year, spreading potential dilution. The filing aligns the director’s incentives with shareholder value but, by itself, does not signal immediate changes to Immix Biopharma’s financial outlook.
Immix Biopharma, Inc. (IMMX) – Form 4 filed 06/23/2025
The filing discloses one transaction by Director and 10% owner Yekaterina (Katie) Chudnovsky dated 06/20/2025. She received a stock-option grant for 33,000 shares of common stock with an exercise price of $2.24 per share and an expiration date of 06/20/2035. The option vests in twelve equal monthly installments, contingent on continued board service. The option was acquired at no cost (transaction code “A”).
No non-derivative shares were bought or sold; the filing merely repeats her existing indirect ownership of 3,241,076 common shares held through GKCC, LLC, of which she is the sole member and manager. After the reported transaction, her total beneficial holdings stand at 3,241,076 shares (indirect) plus 33,000 derivative securities (direct).
Overall, the filing signals continued alignment between the director and shareholders through a sizeable existing stake and modest additional option incentives. The transaction does not materially alter the company’s share count or insider ownership structure.
Form 4 overview: Immix Biopharma, Inc. (ticker: IMMX) filed a Form 4 reporting an open-market purchase by Chief Financial Officer and Director Gabriel S. Morris on 18 June 2025.
- Transaction details: Mr. Morris bought 2,225 common shares at a volume-weighted average price of $2.279 per share (code “P”).
- Direct ownership after transaction: 288,059 common shares held in his own name (ownership code “D”).
- Indirect ownership: 270,844 shares held through Alwaysraise LLC and 24,141 shares held through Alwaysraise Ventures I LP (ownership code “I”). For both entities, Mr. Morris disclaims beneficial ownership except to the extent of his pecuniary interest.
- No derivative securities were reported in Table II.
- The filing was electronically signed by Mr. Morris on 20 June 2025.
The Form 4 reflects Mr. Morris’ latest equity position and provides investors with an updated view of insider holdings as of 18 June 2025.